Brokers Offer Predictions for Gossamer Bio FY2030 Earnings

Key Points

• HC Wainwright projects FY2030 EPS of $0.78 and rates Gossamer Bio a "Buy" with a $10 price target, a sharp contrast to the current consensus estimate of ($0.28) per share.
• Analyst sentiment is mixed but leans positive — the stock has an average rating of "Moderate Buy" with an average price target of $8.60; GOSS trades near $2.35 (market cap ~$544M) and shows heavy institutional accumulation (~81.23% ownership) after large stake increases by several funds.

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Research analysts at HC Wainwright issued their FY2030 EPS estimates for Gossamer Bio in a research note issued on Tuesday, February 10th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of $0.78 for the year. HC Wainwright currently has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share.

Several other research analysts have also recently issued reports on GOSS. Wall Street Zen cut Gossamer Bio from a "hold" rating to a "sell" rating in a research note on Friday, January 23rd. Weiss Ratings restated a "sell (d-)" rating on shares of Gossamer Bio in a research note on Thursday, January 22nd. Finally, Barclays started coverage on shares of Gossamer Bio in a research report on Tuesday, January 27th. They issued an "overweight" rating and a $9.00 target price for the company. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $8.60.

Gossamer Bio Price Performance

GOSS opened at $2.35 on Thursday. The stock's 50 day moving average price is $2.90 and its 200 day moving average price is $2.67. The stock has a market cap of $543.92 million, a P/E ratio of -3.41 and a beta of 1.93. Gossamer Bio has a 12 month low of $0.76 and a 12 month high of $3.87.

Institutional Investors Weigh In On Gossamer Bio

Several hedge funds and other institutional investors have recently bought and sold shares of GOSS. Millennium Management LLC lifted its stake in Gossamer Bio by 629.3% during the third quarter. Millennium Management LLC now owns 3,619,329 shares of the company's stock valued at $9,519,000 after buying an additional 3,123,081 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Gossamer Bio by 4,196.2% during the third quarter. Bank of America Corp DE now owns 2,881,904 shares of the company's stock valued at $7,579,000 after acquiring an additional 2,814,824 shares during the period. UBS Group AG lifted its position in shares of Gossamer Bio by 785.7% in the 3rd quarter. UBS Group AG now owns 2,770,046 shares of the company's stock valued at $7,285,000 after acquiring an additional 2,457,304 shares in the last quarter. Geode Capital Management LLC boosted its stake in Gossamer Bio by 100.4% in the 2nd quarter. Geode Capital Management LLC now owns 4,555,080 shares of the company's stock worth $5,604,000 after purchasing an additional 2,282,632 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in Gossamer Bio by 498.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,792,114 shares of the company's stock worth $5,556,000 after purchasing an additional 1,492,532 shares during the period. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company's lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.